NCT02244190已完成1 期
Bioequivalence of Two Different Oral Solutions of 500 mg of Tipranavir (New Formulation vs. Current Formulation) Administered in Combination With 200 mg of Ritonavir (Oral Solution) to Healthy Volunteers (an Open-label, Randomised, Single Dose, Two-way Crossover Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 主要终点
- AUC0-∞ (area under the concentration-time curve of drug in plasma over the time interval from 0 extrapolated to infinity) for tipranavir
研究概览
简要总结
To establish the bioequivalence of the new tipranavir oral solution formulation with the current tipranavir oral solution formulation following single-dose administration. In each case, 500 mg tipranavir was coadministered with 200 mg ritonavir.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy males and females according to the following criteria based upon a complete medical history, including the physical examination, vital signs (BP, PR), 12-lead ECG, clinical laboratory tests
- •Age ≥ 18 and ≤ 55 years
- •BMI ≥ 18.5 and ≤ 29.9 kg/m2 (Body Mass Index) and body weight > 55 kg
- •Signed and dated written informed consent prior to admission to the study in accordance with Good Clinical Practice and the local legislation
排除标准
- •Any finding of the medical examination (including BP, PR and ECG) deviating from normal and of clinical relevance
- •Any evidence of a clinically relevant concomitant disease
- •Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic, immunological or hormonal disorders
- •Surgery of the gastrointestinal tract (except appendectomy)
- •Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or neurological disorders
- •History of relevant orthostatic hypotension, fainting spells or blackouts.
- •Chronic or relevant acute infections
- •History of relevant allergy/hypersensitivity (including allergy to tipranavir or ritonavir or their excipients)
- •Intake of drugs with a long half-life (> 24 hours) within at least one month or less than 10 half-lives of the respective drug prior to administration of the trial drug or during the trial
- •Cytochrome P 450 (CYP3A4)-inhibiting drugs (e.g. itraconazole, ketoconazole, protease inhibitors, erythromycin, clarithromycin, telithromycin, nefazodone, cyclosporin, verapamil, amiodarone, diltiazem), CYP3A4 inducing drugs (e.g. St. John´s wort [Hypericum perforatum], rifampin, dexamethasone) or CYP3A4 substrates (e.g. triazolam, sertraline); further drugs which might reasonably influence the results of the trial (e.g. drugs which contain polyethylene glycol) or drugs that prolong the QT/corrected QT interval interval (based on the knowledge at the time of protocol preparation) within 14 days prior to first administration of the trial drug or during the trial
- •Participation in another trial with an investigational drug within two months prior to administration of the trial drug or during the trial
- •Smoker (> 10 cigarettes or > 3 cigars or > 3 pipes/day)
- •Inability to refrain from smoking within 24 hours before or after administration of the trial drug
- •Alcohol abuse (more than 60 g/day)
- •Drug abuse
- •Blood donation (more than 100 mL within four weeks prior to administration of the trial drug or during the trial)
- •Excessive physical activities (within one week prior to administration of the trial drug or during the trial)
- •Any laboratory value outside the reference range that is of clinical relevance
- •Inability to comply with dietary regimen of trial site
- •A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a QTc interval >450 ms)
- •A history of additional risk factors for Torsades de Pointes (TdP), e.g., heart failure, hypokalaemia, family history of Long QT Syndrome
- •Known hypersensitivity to antiretroviral drugs (marketed or experimental use as part of clinical research studies)
- •Personal or family history of coagulation or bleeding disorders or bleeding tendencies
- •Intake of vitamin E within 14 days prior to the first drug administration of this trial or during the trial
- •Transaminase values (ALT /AST) greater than the upper limit of the normal laboratory reference range during screening
- •For female subjects:
- •Pregnancy or positive pregnancy test, or planning to become pregnant during the study or within 1 month of study completion
- •No adequate contraception during the study and until 1 month of study completion, i.e. not any of the following: implants, injectables, combined oral contraceptives, intrauterine device, sexual abstinence (for at least 1 month prior to enrolment), vasectomised partner (vasectomy performed at least 1 year prior to enrolment), or surgical sterilisation (incl. hysterectomy). Females who do not have a vasectomised partner, are not sexually abstinent or surgically sterile will be asked to additionally use barrier contraception methods (e.g. condom, diaphragm with spermicide).
- •Lactation period
研究组 & 干预措施
new Tipranavir + Ritonavir
Experimental
干预措施: Tipranavir (Drug)
new Tipranavir + Ritonavir
Experimental
干预措施: Ritonavir (Drug)
current Tipranavir + Ritonavir
Active Comparator
干预措施: Tipranavir (Drug)
current Tipranavir + Ritonavir
Active Comparator
干预措施: Ritonavir (Drug)
结局指标
主要结局
AUC0-∞ (area under the concentration-time curve of drug in plasma over the time interval from 0 extrapolated to infinity) for tipranavir
时间窗: up to 72 hours after drug administration
Cmax (maximum measured concentration of drug in plasma) for tipranavir
时间窗: up to 72 hours after drug administration
次要结局
- CLpo/F (apparent clearance of drug after oral administration)(up to 72 hours after drug administration)
- AUC0-tz (area under the concentration-time curve of drug in plasma over the time interval from 0 to the time of the last quantifiable data point)(up to 72 hours after drug administration)
- λz (terminal rate constant of drug in plasma)(up to 72 hours after drug administration)
- t1/2 (terminal half-life of drug in plasma)(up to 72 hours after drug administration)
- Number of patients with adverse events(up to 43 days)
- Number of patients with clinically significant findings in vital signs(up to 43 days)
- AUC0-∞ for ritonavir(up to 72 hours after drug administration)
- Cmax for ritonavir(up to 72 hours after drug administration)
- tmax (time from dosing to the maximum concentration of drug in plasma)(up to 72 hours after drug administration)
- Vz/F (apparent volume of distribution during the terminal phase λz following an extravascular dose)(up to 72 hours after drug administration)
- MRTpo (mean residence time of drug in the body after oral administration)(up to 72 hours after drug administration)
- Number of patients with clinically significant findings in laboratory tests(up to 43 days)
- Number of patients with clinically significant findings in 12-lead electrocardiogram(up to 43 days)
- Assessment of tolerability by investigator on a 4-point scale(Day 4 of each treatment period)
研究者
相似试验
已完成
1 期
Bioavailability of Tipranavir/Ritonavir Paediatric Solution Compared to Tipranavir/Ritonavir Capsules in Healthy Female and Male SubjectsHealthyNCT02251158Boehringer Ingelheim30
已完成
1 期
A Study To Determine If Two Different Versions Of Topotecan Have The Same Potency In Patients With Advanced Solid TumorsLung Cancer, Small CellNCT00259935GlaxoSmithKline107
已完成
1 期
A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy PeopleHealthy VolunteersType 2 DiabetesNCT05227196Novo Nordisk A/S546
已完成
1 期
Bioequivalence Study for Terbinafine 250 mgMycosesNCT01772212GlaxoSmithKline30
已完成
1 期
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Topiramate Tablets Under Fasted ConditionsHealthyNCT00939692Torrent Pharmaceuticals Limited26